Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)Domenico Russo, Anna Paola Iori, Francesca Bonifazi et al.|Bone Marrow Transplantation|2021Cited by 20
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld StudyMichele Malagola, Domenico Russo, Nicola Polverelli et al.|Transplantation Direct|2023Cited by 10
Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2007Cited by 3
Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.Elena Zamagni, Michèle Cavo, Lelia Valdrè et al.|Blood|2007Cited by 1
Final analysis of the multicenter phase II "Bologna 2002" study incorporating thalidomide-dexamethasone (thal-dex) into up-front double autologous stem-cell transplantation (ASCT) for multiple myelomaElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Unknown|2009Cited by 0